Patents by Inventor Mary Mathieu

Mary Mathieu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies that bind CD3 Epsilon
    Patent number: 12258406
    Abstract: Provided herein are methods and compositions relating to CD3 libraries having nucleic acids encoding for a scaffold comprising a CD3 domain. CD3 libraries described herein encode for immunoglobulins such as antibodies.
    Type: Grant
    Filed: March 23, 2022
    Date of Patent: March 25, 2025
    Assignee: Twist Bioscience Corporation
    Inventors: Aaron Sato, Qiang Liu, Mary Mathieu, Linya Wang
  • SINGLE DOMAIN ANTIBODIES FOR SARS-COV-2
    Publication number: 20230192819
    Abstract: Provided herein are methods and compositions relating to libraries of optimized antibodies having nucleic acids encoding for an antibody comprising modified sequences. Libraries described herein comprise nucleic acids encoding SARS-CoV-2 or ACE2 antibodies. Further described herein are protein libraries generated when the nucleic acid libraries are translated. Further described herein are cell libraries expressing variegated nucleic acid libraries described herein.
    Type: Application
    Filed: August 17, 2022
    Publication date: June 22, 2023
    Inventors: Aaron SATO, Qiang LIU, Mary MATHIEU, Ana G. LUJAN HERNANDEZ
  • VARIANT NUCLEIC ACID LIBRARIES FOR CD3
    Publication number: 20220348659
    Abstract: Provided herein are methods and compositions relating to CD3 libraries having nucleic acids encoding for a scaffold comprising a CD3 domain. CD3 libraries described herein encode for immunoglobulins such as antibodies.
    Type: Application
    Filed: March 23, 2022
    Publication date: November 3, 2022
    Inventors: Aaron SATO, Qiang LIU, Mary MATHIEU, Linya WANG
  • Anti-CLL-1 antibodies and methods of use
    Patent number: 11466087
    Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
    Type: Grant
    Filed: October 21, 2019
    Date of Patent: October 11, 2022
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu
  • Anti-CLL-1 Antibodies and Methods of Use
    Publication number: 20200148774
    Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
    Type: Application
    Filed: October 21, 2019
    Publication date: May 14, 2020
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu
  • Anti-CLL-1 antibodies and methods of use
    Patent number: 10501545
    Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: December 10, 2019
    Assignee: Genentech, Inc.
    Inventors: Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu
  • Anti-HER2 antibodies and methods of use
    Patent number: 10377825
    Abstract: The invention provides anti-HER2 antibodies, including anti-HER2 antibodies of improved stability or affinity, and methods of using the same.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: August 13, 2019
    Assignee: Genentech, Inc.
    Inventors: Mary Mathieu, Mark Dennis
  • HUMANIZED ANTI-EBOLA VIRUS GLYCOPROTEIN ANTIBODIES AND METHODS OF USE
    Publication number: 20180362620
    Abstract: The present invention relates to anti-Ebola virus envelope glycoprotein antibodies. The invention further relates to diagnostic methods which utilize the anti-Ebola virus glycoprotein antibodies and to pharmaceutical compositions which employ these antibodies therapeutically and prophylactically.
    Type: Application
    Filed: November 22, 2017
    Publication date: December 20, 2018
    Applicant: Genentech, Inc.
    Inventors: Mark Dennis, Mary Mathieu
  • ANTI-HER2 ANTIBODIES AND METHODS OF USE
    Publication number: 20180094056
    Abstract: The invention provides anti-HER2 antibodies, including anti-HER2 antibodies of improved stability or affinity, and methods of using the same.
    Type: Application
    Filed: December 14, 2017
    Publication date: April 5, 2018
    Applicant: Genentech, Inc.
    Inventors: Mary Mathieu, Mark Dennis
  • ANTI-CLL-1 ANTIBODIES AND METHODS OF USE
    Publication number: 20160368994
    Abstract: The present invention relates to anti-CLL-1 antibodies including anti-CLL-1 antibodies comprising a CLL-1 binding domain and a CD3 binding domain (e.g., anti-CLL-1/CD3 T cell dependent bispecific (TDB) antibody) and methods of using the same.
    Type: Application
    Filed: June 14, 2016
    Publication date: December 22, 2016
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Steven R. Leong, Wei-Ching Liang, Mary Mathieu, Andrew G. Polson, Bing Zheng, Xiaocheng Chen, Cecilia Pui Chi Chiu, Mark S. Dennis, Allen Ebens, Yan Wu